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ABSTRACT
The analysis of plasma circulating tumour nucleic acids provides a non-invasive
approach to assess disease burden and the genetic evolution of tumours in response
to therapy. BRAF splicing variants are known to confer melanoma resistance to BRAF
inhibitors. We developed a test to screen cell-free RNA (cfRNA) for the presence of
BRAF splicing variants. Custom droplet digital PCR assays were designed for the
detection of BRAF splicing variants p61, p55, p48 and p41 and then validated using
RNA from cell lines carrying these variants. Evaluation of plasma from patients with
reported objective response to BRAF/MEK inhibition followed by disease progression
was revealed by increased circulating tumour DNA (ctDNA) in 24 of 38 cases at the
time of relapse. Circulating BRAF splicing variants were detected in cfRNA from 3 of
these 38 patients; two patients carried the BRAF p61 variant and one the p55 variant.
In all three cases the presence of the splicing variant was apparent only at the time of
progressive disease. BRAF p61 was also detectable in plasma of one of four patients
with confirmed BRAF splicing variants in their progressing tumours. Isolation and
analysis of RNA from extracellular vesicles (EV) from resistant cell lines and patient
plasma demonstrated that BRAF splicing variants are associated with EVs. These
findings indicate that in addition to plasma ctDNA, RNA carried by EVs can provide
important tumour specific information.
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INTRODUCTION

mRNAs from sera of patients with melanoma, breast
cancer, and other malignancies [20–24]. However, the
possibility that extracellular RNA could survive in
the blood has not been widely accepted, due to plasma
containing potent ribonucleases capable of degrading
cell-free RNA [25]. Regardless of this, studies have
documented the presence of ctRNA in serum/plasma of
cancer patients [26, 27].
Extracellular vesicles (EVs) are known to contain
various RNA types, including microRNA, mRNA and
circular RNA [28]. EV RNA has been described as
having a substantial role in the transfer and movement
of epigenetic information and is stable enough for whole
transcriptome sequencing [29–31]. It is plausible that
plasma cell-free RNA (cfRNA) is a mixture of RNA
protected by RNA binding proteins and RNA contained
within EVs. Here we explore whether alternative BRAF
splicing variants can be detected in melanoma patients
who have developed resistance to BRAF inhibitor
therapy. We report a new methodological approach based
on digital droplet polymerase chain reaction (ddPCR) to
assess the presence of BRAF splicing variants in plasma
cfRNA and EV-derived RNA. We interrogated plasma
from 38 melanoma patients identified as having clinically
diagnosed treatment resistance after initial response to
BRAF inhibitor monotherapy or BRAF/MEK inhibitor
combination. In addition, cfRNA was interrogated
from an additional five patients who were confirmed
to have tumour specific BRAF splicing variants in their
progressing tumours. Finally, we evaluated the presence of
BRAF splicing variants in EV RNA isolated from plasma
of two melanoma patients failing BRAF inhibition.

Mutations in the serine/threonine kinase BRAF
are found in 40% of melanomas [1]. The most prevalent
mutation in melanoma is BRAF V600E, which
constitutively activates downstream mitogen-activated
protein kinase (MAPK) signalling. Introduction of
single agent BRAF mutant inhibitors (BRAFi), such
as vemurafenib and dabrafenib, revolutionised the
treatment of metastatic melanomas [2, 3]. Furthermore,
the combination of BRAF and MEK inhibitors (such
as dabrafenib and trametinib, or vemurafenib and
cobimetinib) improved tumour response rate and
progression-free survival, while attenuating some of the
serious adverse events observed with monotherapy [4, 5].
However, even with combination therapies, resistance to
MAPK inhibition remains a major challenge in clinical
care, with the majority of patients progressing within 10
months [6]. Identification of the mechanism of resistance
to targeted therapies in individual patients may offer new
insights into strategies for overcoming resistance.
Resistance to BRAF inhibitors usually involves
MAPK reactivation, via mutations in NRAS or MAP2K1/2,
upregulation of receptor tyrosine kinases, mutant BRAF
gene amplification or alternative BRAF splicing [7–
10]. In around 30% of resistant tumours, resistance to
BRAF inhibition is conferred by alternative splicing via
generation of BRAF isoforms lacking the RAS binding
domain (RBD) encoded by exons 3–5 [7, 11]. In the
absence of the RBD, these BRAF isoforms dimerise even
in the presence of low levels of RAS, conferring and
conferring resistance to BRAF inhibition [12]. Four BRAF
splicing variants, referred to as p61, p55, p48 and p41
were named based on their predicted molecular weight
(Figure 1A).
The analysis of tumour-derived biomarkers in
blood of cancer patients is transforming clinical cancer
pathology. Circulating tumour DNA (ctDNA) has emerged
as a non-invasive biomarker to track tumour burden and
allow monitoring of the cancer genome in blood across
several malignancies including melanoma [13, 14]. We,
and others, have previously demonstrated that increased
melanoma ctDNA levels and the appearance of circulating
mutations associated with of acquired resistance, provide
highly specific, early information of relapse during BRAF
targeted therapies [15, 16]. The latter supports a clinical
model that incorporates the analysis of ctDNA in patients
undergoing BRAF-inhibitor therapies as a routine test
to detect early relapse and resistance [13, 14]. However,
resistance involving aberrant splicing variants, cannot
be detected through ctDNA analysis, and can only be
identified using RNA.
Circulating tumour-derived cell free RNA or
circulating tumour RNA (ctRNA) can be found in plasma
from patients with cancer [17–19]. Various studies have
also demonstrated the ability to amplify tumour-related
www.oncotarget.com

RESULTS
Development of a sensitive assay for detection of
BRAF splicing variants in plasma
We developed ddPCR assays for the detection
of alternative BRAF splicing variants: p61, p55, p48
and p41, which are associated with resistance to BRAF
inhibition, as well as the canonical full length BRAF
(pFL) (Figure 1A). The assays were validated using three
melanoma cell lines with resistance to BRAF inhibition
and known to express alternative BRAF splicing variants
(Figure 1B). As previously reported, SK-Mel-28. BR4
expresses BRAF p55 (exon 4-10∆), SMU027 expresses
BRAF p48 (exon 2-8∆) and WMD009 expresses
BRAF p41 (exon 2-10∆) [9, 32]. Surprisingly without
amplification all cell lines carry the BRAF p61, albeit at
lower concentrations in comparison to the dominant splice
variant expressed. Similarly, SMU027 expressed low
levels of BRAF p41 compared to WMD009.
To enhance sensitivity of detection of BRAF splicing
variants, a pre-amplification step was introduced. This
resulted in a significant enhancement of the signal without
4017
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loss of specificity (Figure 1B). Importantly, the introduced
pre-amplification step maintained a linear relation between
copies of input cDNA and output BRAF splicing variant
copies (R2 = 0.9986, p < 0.0001), with a 6,396 ± 569 fold
increase in BRAF splicing variant copies (Supplementary
Figure 2).
We tested plasma from nine healthy volunteers, to
confirm that the BRAF splicing variants are not commonly
found in normal plasma and that the assay does not
introduce artefacts or induce false detection of BRAF
alternative splicing variants (Supplementary Figure 3).

trametinib therapy) with detectable ctDNA at progression.
Of those, seven had additional NRAS Q61 mutations and
one had a BRAF gene amplification detectable in plasma
(Figure 2 and Supplementary Table 1).
Three patients (MM175, MM493 and MM878) had
detectable BRAF splicing variants in plasma using our
assay, indicating the presence of ctRNA. BRAF splicing
variants were not detected in the pre-treatment plasma
(MM493, MM878) despite clear detectable ctDNA
(Figure 3). Unfortunately, no plasma collected at baseline
was available from MM175 for BRAF splicing variant
assessment.
MM175 presented with multiple spine, rib and liver
metastases. The patient received dabrafenib/trametinib
combination treatment and showed a partial response at 5
weeks, with undetectable ctDNA (Figure 3A). Subsequent
scans confirmed progression with the patient being
moved onto ipilimumab immunotherapy. Analysis of
plasma ctRNA at the final point of dabrafenib/trametinib
progression (21 weeks) and after change of therapy to
ipilimumab (38 weeks), revealed that the BRAF splicing
variant p55 was present only at the time of progression
but undetectable while on ipilimumab treatment, despite
having sustained BRAF V600K ctDNA levels.
MM493 presented with multiple brain, lung and
abdomen metastases. One brain metastasis was resected
while and the others were treated with whole brain
radiotherapy. This patient received dabrafenib/trametinib
combination treatment with partial response at 8 weeks
and limited decrease in ctDNA (Figure 3B). BRAF p61,

Analysis of BRAF splicing variants in plasma of
melanoma patients
We prospectively collected longitudinal plasma
samples from 38 patients: 7 vemurafenib and 31 dabrafenib/
trametinib treated cases (Supplementary Figure 4). Of the
7 vemurafenib cases, 2 had baseline plasma for ctDNA
analysis, and of these 1 experienced a decrease in mutant
BRAF during treatment (MM143), while the other had
an increase in mutant BRAF copies during treatment
(MM141). Of the 31 dabrafenib/trametinib cases, 25 had
assessable baseline plasma, and of these 24 cases had
detectable ctDNA (as mutant BRAF copies) at baseline.
In 19 of the 24 cases, ctDNA decreased during treatment
in comparison to the baseline sample. Analysis of blood
samples collected at the time of progressive disease (red
points – Supplementary Figure 4), identified 29 patients
(5 on vemurafenib and 24 on combination dabrafenib/

Figure 1: BRAF splice variants detection by droplet digital PCR. (A) BRAF exon organisation of the splicing variants and

location of primers and probes used for detection of splicing variants. (B) Droplet digital PCR Ch1,1D plots of each BRAF splicing
detection assay of melanoma cell lines carrying BRAF splicing variants, with and without the pre-amplification, (PreAmp) step.
www.oncotarget.com
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but no other BRAF splicing variants, was detected at
the time of progression (17 weeks, Figure 3B). Plasma
collected at baseline, during response (10 weeks) or
after starting pembrolizumab (25 weeks) did not have
detectable BRAF splicing variants. BRAF V600E ctDNA
was detectable in this patient at all four-time points
analysed but became undetectable by week 54 in response
to treatment with pembrolizumab.
The third patient (MM878) presented with
widespread melanoma in lung, lymph node, adrenal, bone
and gallbladder. The patient was placed on dabrafenib/
trametinib combination treatment and a partial metabolic
response was observed 5 weeks later which was
concordant with a decrease from 458 copies/ml to 56
copies/ml decrease in BRAF V600E ctDNA (Figure 3C).
At the time of progression additional skeletal metastases
were observed by PET scan 18 weeks into therapy, with
ctDNA levels significantly increased to 458 copies/ml,
with the PET scan confirming progression of several
skeletal metastases. The BRAF p61 variant was detectable
in plasma at the point of progression, but was undetectable
at baseline or the first follow up sample collected 4 weeks
into therapy (Figure 3C).
To validate our findings, we next tested the plasma
derived from five melanoma patients that were treated
with vemurafenib monotherapy who developed resistance.

Tumour samples obtained at the time of progression had
confirmed BRAF splicing variants by transcriptome
analysis [8] (Figure 4). We analysed plasma samples
from these patients collected near the time of resecting
the progressed tumour. Only one of these five cases
(MIA_10) had a detectable splicing variant (BRAF p61)
in plasma which was concordant with the results of the
matched tumour sample. BRAF splicing variants were not
detectable in the baseline plasmas from theses patient.

BRAF splicing variants are associated with
extracellular vesicles
Plasma extracellular RNAs are thought to be
carried by extracellular vesicles [33]. To evaluate whether
BRAF splicing variants are found in EVs, we analysed
extracellular vesicles extracted from the plasma of patients
MM493 and MM878. EVs isolated from the supernatant
of SK-Mel-28. BR4 cell line and from the plasma of a
healthy control were used as positive and negative
controls, respectively.
The effective isolation of EVs was confirmed
by western blot analysis, with positive signal for the
tetraspanins CD9, CD63, CD81 and Tumour Susceptibility
Gene 101 (TSG101), while negative for the cellular
marker calnexin (Figure 5A and Supplementary Figure 5).

Figure 2: Clinical and ctDNA profile of patients that showed clinical progressive disease to targeted therapy. Overview

of ctDNA results (copies/mL plasma) from BRAF, NRAS, BRAF splicing and BRAF amplification in 38 melanoma patients. Each column is
an individual patient, showing their clinical characteristics, quantitative ctDNA results (copies/ml or µl of plasma) and presence of BRAF
amplification. *BRAF V600E c.1799_1800GT>AA, p. (Val600Glu), also known as BRAF V600E2 mutation.
www.oncotarget.com
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Transmission electron microscopy (TEM) was used to
visualise the extracted EVs, demonstrating the presence
of exosomes with a size of 100 nm (Figure 5B). Analysis
of EV RNA from SK-Mel-28. BR4 cells confirmed the
presence of BRAF p61 and BRAF FL, while EV RNA
from healthy volunteer only carried BRAF FL variants.
EV RNA from both MM493 and MM878 contained BRAF
p61 transcripts (Figure 5C).

prevalence of approximately 30% for splicing variants
[8, 10]. Long et al. suggested that BRAF splicing were
unlikely to occur in combination therapy as MAPK
signalling driven by such variants will require MEK
activity and therefore will remain sensitive to MEK
inhibitors [9, 34]. Nevertheless, we did not detect BRAF
splicing variants in any of the 7 patients treated with
vemurafenib monotherapy. In contrast, we observed
BRAF splicing variants in 3 of 31 patients treated with
combination BRAF/MEK inhibitors. A study by Wagle
et al., reported the detection of BRAF p41 in the posttreatment tumour of 1 out of 5 patients that developed
resistance to dabrafenib/trametinib [35].
In this study, we failed to detect BRAF splicing
variants in 4 of 5 patients for which the tumours were
confirmed to carry BRAF splicing variants by tissue
analysis. The isolation and presence of circulating RNA
was confirmed in all samples through the presence of
BRAF full length. Moreover, we showed that our method
had high analytical sensitivity and specificity. However,
several technical and biological reasons may explain the
low clinical sensitivity of the test. Similar to ctDNA,
ctRNA detection is likely to be affected by tumour
burden, metabolic activity and location of the tumour [36,
37]. In addition, pre-analytical conditions have not been
optimised for the preservation and extraction of ctRNA or

DISCUSSION
The emergence of BRAF splicing variants is a
common mechanism of escape to BRAF inhibition in
melanoma [10, 12]. Elucidation of the molecular escape
mechanisms usually requires the sourcing of tumour
tissue at the time of progressive disease. Here we show
that tumour specific splicing variants, known to mediate
treatment resistance, can be detected in plasma.
Our study demonstrated the detection of resistance
mediating BRAF splicing variants in ctRNA of melanoma
patients failing BRAF inhibiting therapies. Moreover, we
showed that these BRAF splicing variants are co-purified
or associated with EVs.
The frequency at which we detect splicing variants
in this cohort was low. Tumour analyses within cohorts
treated with BRAF inhibiting monotherapies suggest a

Figure 3: Detection of splice variants in the combination therapy cohort. Three patients undergoing combination BRAFi

therapy were positive for a splicing variant. Patients MM175 (A) and patients MM493 (B), were both positive for the p61 variant at the
point of progressive disease shown in the droplet digital plots. Patient MM878 (C), was positive for the p55 variant also shown in the
droplet digital plot. The longitudinal graphs represent the ctDNA tracking of the activating mutation for the patients. Red, green and grey
dotted lines represent clinical response, progressive disease and stable disease respectively. The singular red dot represents the timeinitial point tested positive for the splicing variants and neighbouring time-points were tested to confirm the presence or absence of the
splicing variants. The coloured area indicates the period during which systemic therapy was administered; colours representing dabrafenib/
trametinib (yellow), ipilimumab (red) and pembrolizumab (blue). Droplet digital plot represents the positivity for the indicated BRAF
splicing variant (blue dots). BRAF full length (BRAF FL, green dots) was use as positive control for RNA extraction and amplification. No
template control and positive control (SK-Mel-28. BR4) were included in each test.
www.oncotarget.com
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EV-derived mRNA in the same way that it has been done
for ctDNA [38].
The presence of ctRNA has been previously reported
in plasma and other body fluids of cancer patients [17,
39–41]. Early reports published by Lo et al. [42] indicated
the presence of tumour derived ctRNA in the plasma of
nasopharyngeal carcinoma patients. Beyond this, ctRNA
analysis has been expanded primarily into cancer detection
cancer or monitoring response [43]. For example, plasma
ctRNA expression of the carcinoembryonic antigen has
been used for diagnosis of early stage prostate cancer
[43] and plasma TERT mRNA levels have demonstrated
to be predictive of response to chemoradiotherapy in
rectal cancers [44]. Thus, ctRNA shows promise as an
additional monitoring tool that can be used in combination
with ctDNA and conventional methods. The advantage of
ctRNA is implied through the assessment of transcriptional
activity of genes.
The effective isolation of EVs was validated using
western blot and transmission electron microscopy. Purity
was confirmed through negativity of calnexin, along with
the positivity of CD9, CD63, CD81 or TSG101 which are
EV associated proteins [45]. Patient MM828-EV sample

was CD81 negative but positive for the other markers,
demonstrating that reliance on one or two markers poses a
risk of false negativity. The heterogeneity of EV-associated
proteins has been reported previously [46–48], suggesting
that a panel of markers is required to validate the presence
of EVs.
EVs have been established as carriers of various
types of RNA, including mRNA, miRNA and long noncoding RNAs [49–51]. The EV RNA from the patients
MM493 and MM878 were found positive for BRAF-p61,
matching the results obtained via their plasma ctRNA.
This suggests that ctRNA may be carried totally or
partially by EVs, and that these vesicles may be protecting
RNA from degradation [49, 52, 53].
Alterations on splicing variants have been shown
to be associated with cancer progression and treatment
resistance [54]. Splicing variants of the androgen receptor,
in particular AR-V7, have been found to be significantly
higher in hormone refractory prostate cancer and is
associated with poor clinical outcomes [55]. Similar to
BRAF-splicing variants, AR-V7 can be detected in plasma
EV RNA [53, 56]. Altogether, this supports an alternative
liquid biopsy modality based on EV RNA or ctRNA.

Figure 4: Detection of BRAF splice variants in patients known to have the splice variant. (A) Patients who had confirmation
of splicing variants in the tumour were investigated to confirm the presence of the variant in the plasma. (B) The droplet digital plot
represents the positivity for p61 in one of the samples.
www.oncotarget.com
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Liquid biopsies have emerged as a non-invasive
approach to assess disease burden and the genetic
evolution of tumours in response to therapy [15, 57–59].
Our study provides a foundation for the detection of
splicing variants in both ctRNA and EV RNA in melanoma
patients failing MAPK inhibition, although its clinical
validity requires further evaluation in independent cohorts.
This work constitutes an important proof of concept that in
addition to plasma ctDNA, ctRNA can provide important
tumour specific information related to the development of
resistance. However pre-analytical conditions for ctRNA
analysis still require optimisation to enable its clinical
application.

approved by the Human Ethics Committees at Edith
Cowan University (No.11543) and Sir Charles Gardner
Hospital (No.2013-246).
Plasma from another five patients treated recruited
at the Melanoma Institute Australia and affiliated hospitals
were included in this study (Melanoma Institute Australia
Biospecimen Bank for Melanoma Research ×11-0289 &
HREC/11/RPAH/444 approved through Sydney Local
Health District). These patients were selected as they were
previously identified as to have BRAF splicing variants
in their progressing tumour after failing treatment with
dabrafenib monotherapy.

Cell culture

MATERIALS AND METHODS

Melanoma cell line 451Lu was obtained from
the Wistar Institute. SK-Mel-28. BR4, SMU027 and
WMD009 were previously reported to carry BRAF
splicing variants [9, 32]. All cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo
Fisher Scientific, Carlsbad, CA, USA) supplemented with
10% Foetal Bovine Serum (Thermo Fisher Scientific,
Carlsbad, CA, USA) at 37°C and 5% CO2.

Patient selection
A total of 38 participants with BRAF mutant
metastatic melanoma were treated with vemurafenib
or with dabrafenib and trametinib combination as per
approved label were enrolled (Supplementary Table 1).
Patients were required to have a recorded objective
response to therapy, either partial or complete confirmed
by CT or PET scans. All patients gave their signed
informed consent before blood collection and data
analysis. The study was performed in accordance with
the Declaration of Helsinki and study protocols were

RNA extraction from cell lines
RNA was extracted using the All Prep DNA/RNA
Mini kit (Qiagen, Hilden, Germany) according to the

Figure 5: Validation of EV isolation from exo-easy and confirmation of splicing variant presence. (A) EVs isolated using

the ExoEasy Kit were tested for the associated markers TSG-101, CD81, CD9 and CD63 and the negative marker Calnexin. Loading was
standardised at 4 µg across all EVs preparations. (B) Electron micrographs were used to determine the presence of EV/exosomes in the
appropriate size range. (C) Droplet digital testing for BRAF p61 (blue dots) and FL-BRAF (green dots) in EV-derived RNA from the
patients, healthy controls and cell line SK-Mel-28. BR4.
www.oncotarget.com
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BRAF amplification analysis

manufacturer’s instructions. RNA was eluted in RNAse
free water and stored at –80°C until analysis.

We optimised a ddPCR assay to assess the presence
of BRAF amplifications using plasma-derived cfDNA.
BRAF copy number was assessed relative to a reference
gene situated in the centromere of chromosome 7 (VOPP1
gene, 7p11.2). For the assessment of BRAF: VOPP1 ratio,
a ddPCR assay was performed with the Bio-Rad QX200
system using custom primers/probe sets against BRAF [60]
and VOPP1 (Bio-Rad, Hercules, CA, USA). The BRAF:
VOPP1 concentration ratio was determined by dividing the
BRAF concentration by the VOPP1 concentration offered
by the QuantaSoft software (Bio-Rad, Hercules, CA, USA).
We first determined the optimal threshold to
define an elevated plasma DNA ddPCR BRAF: VOPP1
ratio using a standard curve of genomic DNA extracted
from healthy volunteer WBC combined with different
percentages of genomic DNA extracted from a melanoma
cell line with known BRAF amplification (Supplementary
Figure 1). Plasma-derived cfDNA from six healthy
volunteers were used to evaluate specificity. Patient
samples with mutant BRAF frequency abundance of 3%
or higher were tested for BRAF amplification.

Circulating nucleic acid extraction
Blood samples were collected into EDTA vacutainer
tubes and plasma was separated within 24 hours by
centrifugation at 300 g for 20 minutes, followed by a
second centrifugation at 4700 g for 10 minutes and then
stored at –80°C until extraction. Plasma cell-free nucleic
acids (cfNA) were isolated from healthy donors and AJCC
stage IV metastatic melanoma patients using the QIAamp
Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) as
per the manufacturer’s instructions. cfNA was eluted in 40 µl
AVE buffer (Qiagen, Hilden, Germany) and stored at –80°C.

Reverse transcription and preamplification
Extracted RNA (5 µl) from all samples were used
for cDNA preparation using the SuperScript® VILO™
cDNA Synthesis Kit (Thermo Fisher Scientific, Carlsbad,
CA, USA) followed by a preamplification using the
TaqMan® PreAmp Master Mix Kit (Thermo Fisher
Scientific, Carlsbad, CA, USA) and all the primers for the
BRAF splicing variants at 180 nM, following manufacturer
cycling conditions (95°C for 10 minutes, followed by 14
cycles of 95°C for 15 seconds and 60°C for 4 minutes,
with a final inactivation step at 99°C for 10 minutes).
Linearity of the pre-amplification step was assessed by
linear regression of a serial dilution curve (Supplementary
Figure 2).

Extracellular vesicle isolation
For EVs isolation, cell lines at 50% confluence were
washed three times with PBS and cultured in DMEM
supplemented with exosome-depleted FBS (Thermo Fisher
Scientific, Carlsbad, CA, USA) for 18 hours at 37°C and 5%
CO2. Following this, cell culture media was harvested and
centrifuged at 300 g for 5 minutes at 4°C. The supernatant
was then transferred to a clean tube and re-centrifuged at
2000 g for 20 minutes. Cleared supernatant was used for EV
isolation using the ExoEasy kit (Qiagen, Hilden, Germany)
following manufacturer’s instructions. EVs were also
isolated from 4 ml of plasma from melanoma patients and
heathy volunteers using the ExoEasy kit (Qiagen) RNA was
isolated from the extracted EVs using the RNeasy Micro
Kit (Qiagen, Hilden, Germany) following manufacturer’s
instructions. RNA was eluted in 14 µL.

Droplet digital PCR
Primer pairs were designed to amplify over the
unique exon-exon junction of each splicing variant,
with probes overlapping the junction (Figure 1A and
Supplementary Table 2). Probes were custom synthesised
by Integrated DNA Technologies (IDT, San Jose, CA,
USA). For ctDNA analysis, samples were analysed for
the presence of BRAF or NRAS mutant DNA as described
previously [15, 60].
Amplifications were performed in a 20 µL reaction
containing 1× ddPCR Supermix for Probes (No dUTP, BioRad), 1× Q solution (Qiagen, Hilden, Germany), 250 nM
of each probe and 900 nM of each primer plus template.
Droplets were generated using the automatic droplet
generator QX200 AutoDG (Bio-Rad, Hercules, CA, USA).
Amplifications were performed using the following cycling
conditions: 1 cycle of 95°C (2.5C/s ramp) for 10 minutes,
40 cycles of 94°C (2.5C/s ramp) for 30 seconds and 55°C
for 1 minute, followed by 1 cycle of 98°C (2.5C/s ramp)
for 10 minutes. Droplets were analysed through a QX200
droplet reader (Bio-Rad, Hercules, CA, USA). QuantaSoft
analysis software (Bio-Rad, Hercules, CA, USA) was used
to acquire and analyse data.
www.oncotarget.com

Western blots
SK-Mel-28 cell lysate was prepared to be used
as positive control. Cells were harvested using trypsin
EDTA (Thermo Fisher Scientific, Carlsbad, CA, USA).
Cell viability was then determined using trypan blue.
Cells were then pelleted at 300 g for five minutes, washed
twice in PBS and lysed with radioimmunoprecipitation
(RIPA) assay buffer (Sigma-Aldrich, St. Louis, Missouri)
containing a complete protease inhibitor tablet (Roche,
Basel, Switzerland). Cell lysates were incubated for 30
minutes on ice prior to being cleared with a 13,000 g spin
for five minutes, with the supernatant being transferred
into a clean tube and stored at –20°C until use.
4023
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EV pellets were resuspended in PBS prior to
mixing 1:1 with RIPA (Sigma-Aldrich, St. Louis,
Missouri) supplemented with protease inhibitor cocktail
(Roche, Basel, Switzerland). EV lysates were incubated
for 30 minutes on ice and then stored at –20°C until use.
Extracted EV proteins were diluted to 1:4 in Lamelli
Buffer (Bio-Rad, Australia), incubated at 95°C for
5 minutes and resolved on a mini TGX 8–16% stain
free gel (Bio-Rad). Proteins were transferred onto a
nitrocellulose blotting membrane using the TransBlot® Turbo™ Transfer System at a constant voltage
of 25V for seven minutes (Bio-Rad, Australia). The
membranes were blocked in 5% milk tris buffered
saline (TBS) for one hour at room temperature before
being probed with primary antibody TSG101 (1:1000,
clone EPR7130B, Abcam), CD9 (1:500, clone
MM2/57, Life-Technologies), CD81 (1:500, clone
1.3.3.22, Life-Technologies). CD63 (1:1000, clone
H5C6, BD-Biosciences, calnexin (1:500, clone AF18,
Life-Technologies) diluted in 0.5% milk TBS 0.05%
Tween 20. The membrane was washed three times for
ten minutes with TBS 0.05% tween and subsequently
probed with secondary antibodies (sheep anti-mouse
IgG-HRP conjugate, polyclonal, 1:2000, GE Healthcare,
donkey anti-rabbit IgG-HRP conjugate, polyclonal,
1:2000, GE Healthcare) diluted in 0.5% milk TBS .05%
Tween 20. Signals were detected with the GE healthcare
Amersham™ ECL™ reagent and were subsequently
imaged using the ChemiDoc™ Touch Imaging System
(Bio-Rad, Hercules, CA, USA). Images were processed
using Image Lab™ software v6.0 (Bio-Rad, Hercules,
CA, USA).
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presented in this paper and reviewed the final manuscript.
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Transmission electron microscopy
EVs were resuspended in PBS and fixed in 2%
paraformaldehyde prior to transfer onto 200 mesh
Formvar-carbon coated copper grids (ProSciTech,
Kirwan, QLD). EVs were adsorbed for 15 minutes at room
temperature prior to being washed four times in filtered
H2O. Samples were then fixed in 1% glutaraldehyde and
contrasted with 1% uranyl acetate for 2 minutes before
being left for 20 minutes to dry at room temperature.
EVs were visualised using JEOL JEM-2100 electron
microscope (JEOL, Tokyo, Japan) at an operating voltage
of 80 kV. Images were captured using an 11M pixel Gatan
Orius digital camera (Gatan, Pleasanton, CA, USA).

REFERENCES
1. Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RPM,
Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B,
Scolyer RA, O’Toole SA, Long GV. The molecular profile of
metastatic melanoma in Australia. Pathology. 2016; 48:188–
193. https://doi.org/10.1016/j.pathol.2015.12.008. [PubMed]
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto
P, Larkin J, Dummer R, Garbe C, Testori A, Maio M,
Hogg D, Lorigan P, Lebbe C, et al. Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N
Engl J Med. 2011; 364:2507–2516. https://doi.org/10.1056/
NEJMoa1103782. [PubMed]

Author contributions
MEC, HR, KM, MZ and ESG designed study.
MEC and ESG performed experiments, analysed data
and drafted the manuscript. HR supplied material. LC,
MP, GM and OR performed experiments and analysed
data. ACM, MAK, TMM, MM, GVL, MSC and AMM
recruited and clinically assessed patients and provided
www.oncotarget.com

3. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer
R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr,
Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C,
et al. Dabrafenib in BRAF-mutated metastatic melanoma:
a multicentre, open-label, phase 3 randomised controlled
4024

Oncotarget

trial. Lancet. 2012; 380:358–365. https://doi.org/10.1016/
S0140-6736(12)60868-X. [PubMed]

13. Diefenbach RJ, Lee JH, Rizos H. Monitoring Melanoma Using
Circulating Free DNA. Am J Clin Dermatol. 2019; 20:1–12.
https://doi.org/10.1007/s40257-018-0398-x. [PubMed]
14. Calapre L, Warburton L, Millward M, Ziman M, Gray
ES. Circulating tumour DNA (ctDNA) as a liquid biopsy
for melanoma. Cancer Lett. 2017; 404:62–69. https://doi.
org/10.1016/j.canlet.2017.06.030. [PubMed]

4. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B,
Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J,
Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JB,
et al. Five-Year Outcomes with Dabrafenib plus Trametinib
in Metastatic Melanoma. N Engl J Med. 2019; 381:626–636.
https://doi.org/10.1056/NEJMoa1904059. [PubMed]
5. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay
G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D,
Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, et al.
Combined Vemurafenib and Cobimetinib in BRAF-Mutated
Melanoma. N Engl J Med. 2014; 371:1867–1876. https://
doi.org/10.1056/NEJMoa1408868. [PubMed]
6. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF,
Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
Kudchadkar R, Burris HA 3rd, Falchook G, et al. Combined
BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 2012; 367:1694–1703. https://doi.
org/10.1056/NEJMoa1210093. [PubMed]
7. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau
G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley
MC, Kefford RF, Chmielowski B, et al. Acquired resistance
and clonal evolution in melanoma during BRAF inhibitor
therapy. Cancer Discov. 2014; 4:80–93. https://doi.
org/10.1158/2159-8290.CD-13-0642. [PubMed]
8. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C,
Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC,
Howle J, Saw R, Thompson JF, et al. BRAF inhibitor
resistance mechanisms in metastatic melanoma: spectrum
and clinical impact. Clin Cancer Res. 2014; 20:1965–1977.
https://doi.org/10.1158/1078-0432.CCR-13-3122. [PubMed]
9. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS,
Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw
RP, Howle J, Hayward NK, Johansson P, et al. Increased
MAPK reactivation in early resistance to dabrafenib/
trametinib combination therapy of BRAF-mutant metastatic
melanoma. Nat Commun. 2014; 5:5694. https://doi.
org/10.1038/ncomms6694. [PubMed]
10. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao
S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H,
Kefford RF, Thompson JF, et al. Acquired BRAF inhibitor
resistance: A multicenter meta-analysis of the spectrum and
frequencies, clinical behaviour, and phenotypic associations
of resistance mechanisms. Eur J Cancer. 2015; 51:2792–
2799. https://doi.org/10.1016/j.ejca.2015.08.022. [PubMed]
11. Freeman AK, Ritt DA, Morrison DK. The importance of
Raf dimerization in cell signaling. Small GTPases. 2013;
4:180–185. https://doi.org/10.4161/sgtp.26117. [PubMed]
12. Poulikakos PI, Persaud Y, Janakiraman M, Kong X,
Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT,
Salton M, Dahlman KB, Tadi M, et al. RAF inhibitor
resistance is mediated by dimerization of aberrantly spliced
BRAF(V600E). Nature. 2011; 480:387–390. https://doi.
org/10.1038/nature10662. [PubMed]
www.oncotarget.com

15. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J,
Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma
C, Cooper A, et al. Circulating tumor DNA to monitor
treatment response and detect acquired resistance in patients
with metastatic melanoma. Oncotarget. 2015; 6:42008–
42018. https://doi.org/10.18632/oncotarget.5788. [PubMed]
16. Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros
A, Mandal AK, Lim KH, Saturno G, Furney SJ, Baenke
F, Pedersen M, Rogan J, et al. Application of Sequencing,
Liquid Biopsies, and Patient-Derived Xenografts for
Personalized Medicine in Melanoma. Cancer Discov. 2016;
6:286–299. https://doi.org/10.1158/2159-8290.CD-15-1336.
[PubMed]
17. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM,
Luketich JD, Godfrey TE. Characterization of amplifiable,
circulating RNA in plasma and its potential as a tool for
cancer diagnostics. Clin Chem. 2004; 50:564–573. https://
doi.org/10.1373/clinchem.2003.028506. [PubMed]
18. Beck TN, Boumber YA, Aggarwal C, Pei J, ThrashBingham C, Fittipaldi P, Vlasenkova R, Rao C, Borghaei
H, Cristofanilli M, Mehra R, Serebriiskii I, Alpaugh RK.
Circulating tumor cell and cell-free RNA capture and
expression analysis identify platelet-associated genes in
metastatic lung cancer. BMC Cancer. 2019; 19:603. https://
doi.org/10.1186/s12885-019-5795-x. [PubMed]
19. Yu XM, Wu YC, Liu X, Huang XC, Hou XX, Wang
JL, Cheng XL, Mao WM, Ling ZQ. Cell-Free RNA
Content in Peripheral Blood as Potential Biomarkers for
Detecting Circulating Tumor Cells in Non-Small Cell
Lung Carcinoma. Int J Mol Sci. 2016; 17:1845. https://doi.
org/10.3390/ijms17111845. [PubMed]
20. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C,
Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun
M, Anker P. Telomerase RNA as a detection marker in
the serum of breast cancer patients. Clin Cancer Res.
2000; 6:3823–3826. https://clincancerres.aacrjournals.org/
content/6/10/3823. [PubMed]
21. Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a
tumor marker: detection of 5T4 mRNA in breast and lung
cancer patient serum. Ann N Y Acad Sci. 2001; 945:172–
178. https://doi.org/10.1111/j.1749-6632.2001.tb03882.x.
[PubMed]
22. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of
tumor messenger RNA in the serum of patients with malignant
melanoma. Clin Cancer Res. 1999; 5:1961–1965. https://
clincancerres.aacrjournals.org/content/5/8/1961. [PubMed]
23. Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva
J, Dominguez G, Provencio M, Espana P, Bonilla F.
4025

Oncotarget

Detection of epithelial tumour RNA in the plasma of colon
cancer patients is associated with advanced stages and
circulating tumour cells. Gut. 2002; 50:530–534. https://
doi.org/10.1136/gut.50.4.530. [PubMed]

34. Vido MJ, Le K, Hartsough EJ, Aplin AE. BRAF Splice
Variant Resistance to RAF Inhibitor Requires Enhanced
MEK Association. Cell Reports. 2018; 25:1501–1510.e3.
https://doi.org/10.1016/j.celrep.2018.10.049. [PubMed]

24. Zhang X, Yang X, Zhang Y, Liu X, Zheng G, Yang Y, Wang
L, Du L, Wang C. Direct Serum Assay for Cell-Free Bmi-1
mRNA and Its Potential Diagnostic and Prognostic Value
for Colorectal Cancer. Clin Cancer Res. 2015; 21:1225–
1233. https://doi.org/10.1158/1078-0432.CCR-14-1761.
[PubMed]

35. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper
ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan
RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, et
al. MAP kinase pathway alterations in BRAF-mutant
melanoma patients with acquired resistance to combined
RAF/MEK inhibition. Cancer Discov. 2014; 4:61–68.
https://doi.org/10.1158/2159-8290.CD-13-0631. [PubMed]

25. Sorrentino S. The eight human “canonical” ribonucleases:
Molecular diversity, catalytic properties, and special
biological actions of the enzyme proteins. FEBS
Lett. 2010; 584:2194–2200. https://doi.org/10.1016/j.
febslet.2010.04.018. [PubMed]

36. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M,
Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah
S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, et
al. Phylogenetic ctDNA analysis depicts early-stage lung
cancer evolution. Nature. 2017; 545:446–451. https://doi.
org/10.1038/nature22364. [PubMed]

26. Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang
Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L. Plasma
extracellular RNA profiles in healthy and cancer patients.
Sci Rep. 2016; 6:19413. https://doi.org/10.1038/srep19413.
[PubMed]

37. McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre
L, Pereira MR, Khattak MA, Meniawy TM, Millward M,
Ziman M, Gray ES. Correlation between circulating tumour
DNA and metabolic tumour burden in metastatic melanoma
patients. BMC Cancer. 2018; 18:726–726. https://doi.
org/10.1186/s12885-018-4637-6. [PubMed]

27. Takahashi K, Ota Y, Kogure T, Suzuki Y, Iwamoto H,
Yamakita K, Kitano Y, Fujii S, Haneda M, Patel T, Ota T.
Circulating extracellular vesicle-encapsulated HULC is a
potential biomarker for human pancreatic cancer. Cancer
Sci. 2020; 111:98–111. https://doi.org/10.1111/cas.14232.
[PubMed]

38. Lampignano R, Neumann MHD, Weber S, Kloten V,
Herdean A, Voss T, Groelz D, Babayan A, Tibbesma
M, Schlumpberger M, Chemi F, Rothwell DG, Wikman
H, et al. Multicenter Evaluation of Circulating CellFree DNA Extraction and Downstream Analyses for the
Development of Standardized (Pre)analytical Work Flows.
Clin Chem. 2020; 66:149–160. https://doi.org/10.1373/
clinchem.2019.306837. [PubMed]

28. Colombo M, Raposo G, Théry C. Biogenesis, Secretion,
and Intercellular Interactions of Exosomes and Other
Extracellular Vesicles. Annu Rev Cell Dev Biol.
2014; 30:255–289. https://doi.org/10.1146/annurevcellbio-101512-122326. [PubMed]

39. Souza MF, Kuasne H, Barros-Filho MC, Cilião HL, Marchi
FA, Fuganti PE, Paschoal AR, Rogatto SR, Cólus IM.
Circulating mRNAs and miRNAs as candidate markers
for the diagnosis and prognosis of prostate cancer. PLoS
One. 2017; 12:e0184094. https://doi.org/10.1371/journal.
pone.0184094. [PubMed]

29. Turchinovich A, Drapkina O, Tonevitsky A. Transcriptome
of Extracellular Vesicles: State-of-the-Art. Front
Immunol. 2019; 10:202–202. https://doi.org/10.3389/
fimmu.2019.00202. [PubMed]
30. Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D,
Gorospe M. RNA in extracellular vesicles. Wiley Interdiscip
Rev RNA. 2017; 8:e1413. https://doi.org/10.1002/
wrna.1413. [PubMed]

40. Pucciarelli S, Rampazzo E, Briarava M, Maretto I, Agostini
M, Digito M, Keppel S, Friso ML, Lonardi S, De Paoli A,
Mescoli C, Nitti D, De Rossi A. Telomere-Specific Reverse
Transcriptase (hTERT) and Cell-free RNA in Plasma as
Predictors of Pathologic Tumor Response in Rectal Cancer
Patients Receiving Neoadjuvant Chemoradiotherapy. Ann
Surg Oncol. 2012; 19:3089–3096. https://doi.org/10.1245/
s10434-012-2272-z. [PubMed]

31. Di Liegro CM, Schiera G, Di Liegro I. Extracellular VesicleAssociated RNA as a Carrier of Epigenetic Information.
Genes (Basel). 2017; 8:240. https://doi.org/10.3390/
genes8100240. [PubMed]
32. Gowrishankar K, Snoyman S, Pupo GM, Becker TM,
Kefford RF, Rizos H. Acquired resistance to BRAF
inhibition can confer cross-resistance to combined BRAF/
MEK inhibition. J Invest Dermatol. 2012; 132:1850–1859.
https://doi.org/10.1038/jid.2012.63. [PubMed]

41. García–Olmo DC, Contreras JD, Picazo MG, López–
Torres J, García–Olmo D. Potential clinical significance of
perioperative levels of mRNA in plasma from patients with
cancer of the larynx or hypopharynx. Head Neck. 2017;
39:647–655. https://doi.org/10.1002/hed.24638. [PubMed]

33. Patton JG, Franklin JL, Weaver AM, Vickers K, Zhang
B, Coffey RJ, Ansel KM, Blelloch R, Goga A, Huang B,
L’Etoille N, Raffai RL, Lai CP, et al. Biogenesis, delivery,
and function of extracellular RNA. J Extracell Vesicles.
2015; 4:27494. https://doi.org/10.3402/jev.v4.27494.
[PubMed]

www.oncotarget.com

42. Lo KW, Lo YMD, Leung SF, Tsang YS, Chan LYS, Johnson
PJ, Hjelm NM, Lee JCK, Huang DP. Analysis of Cell-free
Epstein-Barr Virus-associated RNA in the Plasma of Patients
with Nasopharyngeal Carcinoma. Clin Chem. 1999; 45:1292–
1294. https://doi.org/10.1093/clinchem/45.8.1292. [PubMed]
4026

Oncotarget

43. Papadopoulou E, Davilas E, Sotiriou V, Georgakopoulos E,
Georgakopoulou S, Koliopanos A, Aggelakis F, Dardoufas
K, Agnantis N, Karydas I, Nasioulas G. Cell-free DNA and
RNA in Plasma as a New Molecular Marker for Prostate
and Breast Cancer. Ann N Y Acad Sci. 2006; 1075:235–243.
https://doi.org/10.1196/annals.1368.032. [PubMed]

52. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes
provide a protective and enriched source of miRNA for
biomarker profiling compared to intracellular and cellfree blood. J Extracell Vesicles. 2014; 3:23743. https://doi.
org/10.3402/jev.v3.23743. [PubMed]
53. Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini
C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik
RH, Danesi R. The Detection of Androgen Receptor Splice
Variant 7 in Plasma-derived Exosomal RNA Strongly
Predicts Resistance to Hormonal Therapy in Metastatic
Prostate Cancer Patients. Eur Urol. 2017; 71:680–687.
https://doi.org/10.1016/j.eururo.2016.08.012. [PubMed]

44. Rampazzo E, Del Bianco P, Bertorelle R, Boso C, Perin A,
Spiro G, Bergamo F, Belluco C, Buonadonna A, Palazzari
E, Lonardi S, De Paoli A, Pucciarelli S, et al. The predictive
and prognostic potential of plasma telomerase reverse
transcriptase (TERT) RNA in rectal cancer patients. Br
J Cancer. 2018; 118:878–886. https://doi.org/10.1038/
bjc.2017.492. [PubMed]

54. Escobar-Hoyos L, Knorr K, Abdel-Wahab O. Aberrant
RNA Splicing in Cancer. Annu Rev Cancer Biol.
2019;
3:167–185.
https://doi.org/10.1146/annurevcancerbio-030617-050407. [PubMed]

45. Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D,
Gardiner C, Gho YS, Kurochkin IV, Mathivanan S,
Quesenberry P, Sahoo S, Tahara H, Wauben MH, et
al. Minimal experimental requirements for definition
of extracellular vesicles and their functions: a position
statement from the International Society for Extracellular
Vesicles. J Extracell Vesicles. 2014; 3:26913. https://doi.
org/10.3402/jev.v3.26913. [PubMed]

55. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E,
Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo
J. Ligand-independent androgen receptor variants derived
from splicing of cryptic exons signify hormone-refractory
prostate cancer. Cancer Res. 2009; 69:16–22. https://doi.
org/10.1158/0008-5472.CAN-08-2764. [PubMed]

46. Willms E, Cabañas C, Mäger I, Wood MJA, Vader P.
Extracellular Vesicle Heterogeneity: Subpopulations,
Isolation Techniques, and Diverse Functions in Cancer
Progression. Front Immunol. 2018; 9:738–738. https://doi.
org/10.3389/fimmu.2018.00738. [PubMed]

56. Nimir M, Ma Y, Jeffreys SA, Opperman T, Young F, Khan
T, Ding P, Chua W, Balakrishnar B, Cooper A, De Souza
P, Becker TM. Detection of AR-V7 in Liquid Biopsies of
Castrate Resistant Prostate Cancer Patients: A Comparison
of AR-V7 Analysis in Circulating Tumor Cells, Circulating
Tumor RNA and Exosomes. Cells. 2019; 8:688. https://doi.
org/10.3390/cells8070688. [PubMed]

47. Gyuris A, Navarrete-Perea J, Jo A, Cristea S, Zhou S, Fraser
K, Wei Z, Krichevsky AM, Weissleder R, Lee H, Gygi SP,
Charest A. Physical and Molecular Landscapes of Mouse
Glioma Extracellular Vesicles Define Heterogeneity. Cell
Rep. 2019; 27:3972–3987.e6. https://doi.org/10.1016/j.
celrep.2019.05.089. [PubMed]

57. Wong SQ, Raleigh JM, Callahan J, Vergara IA, Ftouni S,
Hatzimihalis A, Colebatch AJ, Li J, Semple T, Doig K,
Mintoff C, Sinha D, Yeh P, et al. Circulating Tumor DNA
Analysis and Functional Imaging Provide Complementary
Approaches for Comprehensive Disease Monitoring in
Metastatic Melanoma. JCO Precis Oncol. 2017; 1:1–14.
https://doi.org/10.1200/PO.16.00009.

48. Armitage JD, Tan DBA, Cha L, Clark M, Gray ES, Fuller
KA, Moodley YP. A standardised protocol for the evaluation
of small extracellular vesicles in plasma by imaging flow
cytometry. J Immunol Methods. 2019; 468:61–66. https://
doi.org/10.1016/j.jim.2019.03.006. [PubMed]

58. Wang R, Li X, Zhang H, Wang K, He J. Cell-free
circulating tumor DNA analysis for breast cancer and
its clinical utilization as a biomarker. Oncotarget. 2017;
8:75742–75755. https://doi.org/10.18632/oncotarget.20608.
[PubMed]

49. Zhou R, Chen KK, Zhang J, Xiao B, Huang Z, Ju C, Sun J,
Zhang F, Lv XB, Huang G. The decade of exosomal long
RNA species: an emerging cancer antagonist. Mol Cancer.
2018; 17:75. https://doi.org/10.1186/s12943-018-0823-z.
[PubMed]

59. Kruger S, Heinemann V, Ross C, Diehl F, Nagel D,
Ormanns S, Liebmann S, Prinz-Bravin I, Westphalen CB,
Haas M, Jung A, Kirchner T, von Bergwelt-Baildon M, et
al. Repeated mutKRAS ctDNA measurements represent
a novel and promising tool for early response prediction
and therapy monitoring in advanced pancreatic cancer.
Ann Oncol. 2018; 29:2348–2355. https://doi.org/10.1093/
annonc/mdy417. [PubMed]

50. Kitagawa T, Taniuchi K, Tsuboi M, Sakaguchi M, Kohsaki
T, Okabayashi T, Saibara T. Circulating pancreatic cancer
exosomal RNAs for detection of pancreatic cancer. Mol
Oncol. 2019; 13:212–227. https://doi.org/10.1002/18780261.12398. [PubMed]
51. Yoshii S, Hayashi Y, Iijima H, Inoue T, Kimura K, Sakatani
A, Nagai K, Fujinaga T, Hiyama S, Kodama T, Shinzaki S,
Tsujii Y, Watabe K, et al. Exosomal microRNAs derived
from colon cancer cells promote tumor progression by
suppressing fibroblast TP53 expression. Cancer Sci.
2019; 110:2396–2407. https://doi.org/10.1111/cas.14084.
[PubMed]

www.oncotarget.com

60. Reid AL, Freeman JB, Millward M, Ziman M, Gray ES.
Detection of BRAF-V600E and V600K in melanoma
circulating tumour cells by droplet digital PCR. Clin
Biochem. 2015; 48:999–1002. https://doi.org/10.1016/j.
clinbiochem.2014.12.007. [PubMed]

4027

Oncotarget

